;PMID: 4035074
;source_file_1003.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..56] = [t:0..56]
;1)sentence:[e:62..117] = [t:62..117]
;2)section:[e:121..138] = [t:121..138]
;3)sentence:[e:142..232] = [t:142..232]
;4)sentence:[e:233..390] = [t:233..390]
;5)sentence:[e:391..465] = [t:391..465]
;6)sentence:[e:466..626] = [t:466..626]
;7)sentence:[e:627..855] = [t:627..855]
;8)sentence:[e:856..1009] = [t:856..1009]
;9)sentence:[e:1010..1130] = [t:1010..1130]
;10)sentence:[e:1131..1262] = [t:1131..1262]
;11)section:[e:1266..1310] = [t:1266..1310]

;section 0 Span:0..56
;Res Commun Chem Pathol Pharmacol. 1985 Jul;49(1):109-24.
(SEC
  (FRAG (NNP:[0..3] Res) (NNP:[4..10] Commun) (NNP:[11..15] Chem)
        (NNP:[16..22] Pathol) (NNP:[23..32] Pharmacol) (.:[32..33] .)
        (CD:[34..38] 1985) (::[39..46] Jul;49-LRB-) (CD:[46..47] 1)
        (-RRB-:[47..48] -RRB-) (CD:[48..52] :109) (::[52..53] -)
        (CD:[53..55] 24) (.:[55..56] .)))

;sentence 1 Span:62..117
;Kinetics of microsomal metabolism of quinidine in rats.
;[99..108]:substance:"quinidine"
(SENT
  (NP-HLN
    (NP (NN:[62..70] Kinetics))
    (PP (IN:[71..73] of)
      (NP
        (NP (JJ:[74..84] microsomal) (NN:[85..95] metabolism))
        (PP (IN:[96..98] of)
          (NP (NN:[99..108] quinidine)))
        (PP-LOC (IN:[109..111] in)
          (NP (NNS:[112..116] rats)))))
    (.:[116..117] .)))

;section 2 Span:121..138
;Rakhit A, Mico B.
(SEC
  (FRAG (NNP:[121..127] Rakhit) (NNP:[128..129] A) (,:[129..130] ,)
        (NNP:[131..135] Mico) (NNP:[136..138] B.)))

;sentence 3 Span:142..232
;Kinetics of in vitro metabolism of quinidine was investigated using rat liver
; microsomes.
;[177..186]:substance:"quinidine"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[142..150] Kinetics))
      (PP (IN:[151..153] of)
        (NP
          (NP
            (ADJP (FW:[154..156] in) (FW:[157..162] vitro))
            (NN:[163..173] metabolism))
          (PP (IN:[174..176] of)
            (NP (NN:[177..186] quinidine))))))
    (VP (VBD:[187..190] was)
      (VP (VBN:[191..203] investigated)
        (NP-1 (-NONE-:[203..203] *))
        (S-MNR
          (NP-SBJ (-NONE-:[203..203] *))
          (VP (VBG:[204..209] using)
            (NP (NN:[210..213] rat) (NN:[214..219] liver)
                (NNS:[221..231] microsomes))))))
    (.:[231..232] .)))

;sentence 4 Span:233..390
;Quinidine elimination was capacity limited with apparent Michaelis  constant
;(appKM) of 2.6 microM (about 1.2 mg/L) in liver microsomes from  uninduced
;rats.
;[233..242]:substance:"Quinidine"
;[311..316]:quantitative-name:"appKM"
;[321..324]:quantitative-value:"2.6"
;[325..331]:quantitative-units:"microM"
;[339..342]:quantitative-value:"1.2"
;[343..347]:quantitative-units:"mg/L"
(SENT
  (S
    (NP-SBJ-1 (NN:[233..242] Quinidine) (NN:[243..254] elimination))
    (VP (VBD:[255..258] was)
      (NP-ADV (NN:[259..267] capacity))
      (VP (VBN:[268..275] limited)
        (NP-1 (-NONE-:[275..275] *))
        (PP (IN:[276..280] with)
          (NP
            (NP
              (NP (JJ:[281..289] apparent) (NNP:[290..299] Michaelis)
                  (NN:[301..309] constant))
              (NP (-LRB-:[310..311] -LRB-) (NN:[311..316] appKM)
                  (-RRB-:[316..317] -RRB-)))
            (PP (IN:[318..320] of)
              (NP (CD:[321..324] 2.6) (NN:[325..331] microM)
                (PRN (-LRB-:[332..333] -LRB-)
                  (NP
                    (NP
                      (QP (RB:[333..338] about) (CD:[339..342] 1.2))
                      (NN:[343..345] mg))
                    (PP (SYM:[345..346] /)
                      (NP (NN:[346..347] L))))
                  (-RRB-:[347..348] -RRB-))))))
        (PP-LOC (IN:[349..351] in)
          (NP
            (NP (NN:[352..357] liver) (NNS:[358..368] microsomes))
            (PP (IN:[369..373] from)
              (NP (JJ:[375..384] uninduced) (NNS:[385..389] rats)))))))
    (.:[389..390] .)))

;sentence 5 Span:391..465
;Phenobarbital (PB) pretreatment caused induction of quinidine  metabolism.
;[391..404]:substance:"Phenobarbital"
;[406..408]:substance:"PB"
;[443..452]:substance:"quinidine"
(SENT
  (S
    (NP-SBJ
      (NML
        (NML (NN:[391..404] Phenobarbital))
        (NML (-LRB-:[405..406] -LRB-) (NN:[406..408] PB)
             (-RRB-:[408..409] -RRB-)))
      (NN:[410..422] pretreatment))
    (VP (VBD:[423..429] caused)
      (NP
        (NP (NN:[430..439] induction))
        (PP (IN:[440..442] of)
          (NP (NN:[443..452] quinidine) (NN:[454..464] metabolism)))))
    (.:[464..465] .)))

;sentence 6 Span:466..626
;Formation of all three metabolites important in man,  3-hydroxyquinidine,
;quinidine N-oxide and quinidine 10,11-dihydrodiol were PB  inducible (Vmax
;increased).
;[489..500]:substance:"metabolites"
;[520..538]:substance:"3-hydroxyquinidine"
;[540..557]:substance:"quinidine N-oxide"
;[562..589]:substance:"quinidine 10,11-dihydrodiol"
;[595..597]:substance:"PB"
;[610..614]:quantitative-name:"Vmax"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[466..475] Formation))
      (PP (IN:[476..478] of)
        (NP
          (NP
            (NP (DT:[479..482] all) (CD:[483..488] three)
                (NNS:[489..500] metabolites))
            (ADJP (JJ:[501..510] important)
              (PP (IN:[511..513] in)
                (NP (NN:[514..517] man)))))
          (,:[517..518] ,)
          (NP
            (NP (NN:[520..538] 3-hydroxyquinidine))
            (,:[538..539] ,)
            (NP (NN:[540..549] quinidine) (NN:[550..557] N-oxide))
            (CC:[558..561] and)
            (NP (NN:[562..571] quinidine) (NN:[572..589] 10,11-dihydrodiol))))))
    (VP (VBD:[590..594] were)
      (ADJP-PRD (NN:[595..597] PB) (JJ:[599..608] inducible)
        (PRN (-LRB-:[609..610] -LRB-)
          (S
            (NP-SBJ (NN:[610..614] Vmax))
            (VP (VBD:[615..624] increased)))
          (-RRB-:[624..625] -RRB-))))
    (.:[625..626] .)))

;sentence 7 Span:627..855
;To study any direct interaction between PB and  quinidine, PB was also added
;to the microsomal incubate and was found to  decrease the rate constant for
;quinidine metabolism, suggesting inhibition of  quinidine metabolism by PB.
;[667..669]:substance:"PB"
;[675..684]:substance:"quinidine"
;[686..688]:substance:"PB"
;[780..789]:substance:"quinidine"
;[828..837]:substance:"quinidine"
;[852..854]:substance:"PB"
(SENT
  (S
    (S-PRP
      (NP-SBJ (-NONE-:[627..627] *))
      (VP (TO:[627..629] To)
        (VP (VB:[630..635] study)
          (NP
            (NP (DT:[636..639] any) (JJ:[640..646] direct)
                (NN:[647..658] interaction))
            (PP (IN:[659..666] between)
              (NP (NN:[667..669] PB) (CC:[670..673] and)
                  (NN:[675..684] quinidine)))))))
    (,:[684..685] ,)
    (NP-SBJ-1 (NN:[686..688] PB))
    (VP
      (VP (VBD:[689..692] was)
        (ADVP (RB:[693..697] also))
        (VP (VBN:[698..703] added)
          (NP-1 (-NONE-:[703..703] *))
          (PP (TO:[704..706] to)
            (NP (DT:[707..710] the) (JJ:[711..721] microsomal)
                (NN:[722..730] incubate)))))
      (CC:[731..734] and)
      (VP (VBD:[735..738] was)
        (VP (VBN:[739..744] found)
          (S
            (NP-SBJ-1 (-NONE-:[744..744] *))
            (VP (TO:[745..747] to)
              (VP (VB:[749..757] decrease)
                (NP
                  (NP (DT:[758..761] the) (NN:[762..766] rate)
                      (NN:[767..775] constant))
                  (PP (IN:[776..779] for)
                    (NP (NN:[780..789] quinidine) (NN:[790..800] metabolism))))
                (,:[800..801] ,)
                (S-ADV
                  (NP-SBJ (-NONE-:[801..801] *))
                  (VP (VBG:[802..812] suggesting)
                    (NP
                      (NP (NN:[813..823] inhibition))
                      (PP (IN:[824..826] of)
                        (NP (NN:[828..837] quinidine) (NN:[838..848] metabolism)))
                      (PP (IN:[849..851] by)
                        (NP (NN:[852..854] PB))))))))))))
    (.:[854..855] .)))

;sentence 8 Span:856..1009
;While, 3-hydroxyquinidine formation was inhibited  (Vmax decreased and KM
;increased), the formation of quinidine N-oxide was  activated (Vmax
;increased).
;[863..881]:substance:"3-hydroxyquinidine"
;[908..912]:quantitative-name:"Vmax"
;[927..929]:quantitative-name:"KM"
;[959..976]:substance:"quinidine N-oxide"
;[993..997]:quantitative-name:"Vmax"
(SENT
  (S
    (SBAR-ADV (IN:[856..861] While) (.:[861..862] ,)
      (S
        (NP-SBJ-1 (NN:[863..881] 3-hydroxyquinidine) (NN:[882..891] formation))
        (VP (VBD:[892..895] was)
          (VP (VBN:[896..905] inhibited)
            (NP-1 (-NONE-:[905..905] *))
            (PRN (-LRB-:[907..908] -LRB-)
              (S
                (S
                  (NP-SBJ (NN:[908..912] Vmax))
                  (VP (VBD:[913..922] decreased)))
                (CC:[923..926] and)
                (S
                  (NP-SBJ (NN:[927..929] KM))
                  (VP (VBD:[930..939] increased))))
              (-RRB-:[939..940] -RRB-))))))
    (,:[940..941] ,)
    (NP-SBJ-2
      (NP (DT:[942..945] the) (NN:[946..955] formation))
      (PP (IN:[956..958] of)
        (NP (NN:[959..968] quinidine) (NN:[969..976] N-oxide))))
    (VP (VBD:[977..980] was)
      (VP (VBN:[982..991] activated)
        (NP-2 (-NONE-:[991..991] *))
        (PRN (-LRB-:[992..993] -LRB-)
          (S
            (NP-SBJ (NN:[993..997] Vmax))
            (VP (VBD:[998..1007] increased)))
          (-RRB-:[1007..1008] -RRB-))))
    (.:[1008..1009] .)))

;sentence 9 Span:1010..1130
;The formation of quinidine 10,11-dihydrodiol,  although a minor metabolite in
;rat, was also inhibited in presence of PB.
;[1027..1054]:substance:"quinidine 10,11-dihydrodiol"
;[1074..1084]:substance:"metabolite"
;[1127..1129]:substance:"PB"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1010..1013] The) (NN:[1014..1023] formation))
      (PP (IN:[1024..1026] of)
        (NP
          (NP (NN:[1027..1036] quinidine) (NN:[1037..1054] 10,11-dihydrodiol))
          (FRAG (,:[1054..1055] ,) (IN:[1057..1065] although)
            (NP
              (NP (DT:[1066..1067] a) (JJ:[1068..1073] minor)
                  (NN:[1074..1084] metabolite))
              (PP (IN:[1085..1087] in)
                (NP (NN:[1088..1091] rat))))
            (,:[1091..1092] ,)))))
    (VP (VBD:[1093..1096] was)
      (ADVP (RB:[1097..1101] also))
      (VP (VBN:[1102..1111] inhibited)
        (NP-1 (-NONE-:[1111..1111] *))
        (PP (IN:[1112..1114] in)
          (NP
            (NP (NN:[1115..1123] presence))
            (PP (IN:[1124..1126] of)
              (NP (NN:[1127..1129] PB)))))))
    (.:[1129..1130] .)))

;sentence 10 Span:1131..1262
;It is  apparent from this study that PB when administered in vivo would act
;as both  inducer and inhibitor of quinidine metabolism.
;[1168..1170]:substance:"PB"
;[1216..1223]:substance:"inducer"
;[1228..1237]:substance:"inhibitor"
;[1241..1250]:substance:"quinidine"
(SENT
  (S
    (NP-SBJ (PRP:[1131..1133] It))
    (VP (VBZ:[1134..1136] is)
      (ADJP-PRD (JJ:[1138..1146] apparent)
        (PP (IN:[1147..1151] from)
          (NP (DT:[1152..1156] this) (NN:[1157..1162] study)))
        (SBAR (IN:[1163..1167] that)
          (S
            (NP-SBJ (NN:[1168..1170] PB))
            (SBAR-ADV (IN:[1171..1175] when)
              (S
                (NP-SBJ-2 (-NONE-:[1175..1175] *))
                (VP (VBN:[1176..1188] administered)
                  (NP-2 (-NONE-:[1188..1188] *))
                  (ADVP (FW:[1189..1191] in) (FW:[1192..1196] vivo)))))
            (VP (MD:[1197..1202] would)
              (VP (VB:[1203..1206] act)
                (PP (IN:[1207..1209] as)
                  (NP
                    (NP (CC:[1210..1214] both) (NN:[1216..1223] inducer)
                        (CC:[1224..1227] and) (NN:[1228..1237] inhibitor))
                    (PP (IN:[1238..1240] of)
                      (NP (NN:[1241..1250] quinidine)
                          (NN:[1251..1261] metabolism)))))))))))
    (.:[1261..1262] .)))

;section 11 Span:1266..1310
;PMID: 4035074 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1266..1270] PMID) (::[1270..1271] :) (CD:[1272..1279] 4035074)
        (NN:[1280..1281] -LSB-) (NNP:[1281..1287] PubMed) (::[1288..1289] -)
        (NN:[1290..1297] indexed) (IN:[1298..1301] for)
        (NNP:[1302..1310] MEDLINE-RSB-)))
